Influx Healthtech Limited · NSE:INFLUX
Influx Healthtech — H1 FY26 Earnings Presentation
36 slides from Influx Healthtech's earnings presentation, Nov 12, 2025
Slide 1: Exchange covering letter for investor presentation
November 12, 2025 To, Listing Department, National Stock Exchange Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai-400 051 Scrip Code – INFLUX Dear Sir/Madam, Sub.: Analyst/Institutional Investor Earnings Call Presentation. Ref: Regulation 30 read with Para A of Part A
Slide 2: Investor Presentation – H1 FY26 Earnings Update
INVESTOR PRESENTATION – H1 FY26 EARNINGS UPDATE
Slide 3: Agenda
Agenda 1. Performance update 2. About Influx Healthtech Limited 3. Competitive moats 4. Investment rationale 5. Historical business performance 6. Select financial statement data 7. Annexures
Slide 4: Executive Summary – H1 FY26
Executive Summary – H1 FY26 Revenue and profitability Return and capital Presence and Capacity Revenue from operations Return on equity (RoE) Product Range INR 66.8 crs. 22..2% 3,721 Up 39% YoY Vs 37.0% in FY25 Vs 3,559 in FY25 EBIDTA Return on capital employed (RoCE) Client retention INR 14.7 crs.
Slide 5: Performance update and management commentary – H1 FY26
Performance update and management commentary – H1 FY26 ▪ Commercialized below multi-line production facility in H1 FY26, through internal accruals: o 480 kg/day: Tablet production | 24,000 bottles/shift: Liquid production Business updates o 32,000 sachets/shift: Sachet production | 10,000–15,000 bot
Slide 6: Revenue split across segments – H1 FY26
Revenue split across segments – H1 FY26 (₹ crores) Nutraceuticals Cosmetics Ayurvedic Others1 60.1 3.4 2.7 0.6 0.5 44.1 2.1 1.3 H1 FY25 H1 FY26 H1 FY25 H1 FY26 H1 FY25 H1 FY26 H1 FY25 H1 FY26 1% 1% 92% 90% 3% H1 FY25 4% H1 FY26 4% 5% 1 Nutraceuticals Cosmetics Ayurvedic Others 4 1. Others include ve
Slide 7: Agenda
Agenda 1. Performance update 2. 2. About About Influx Influx Healthtech Healthtech Limited Limited 3. Competitive moats 4. Investment rationale 5. Historical business performance 6. Select financial statement data 7. Annexures
Slide 8: Formulation driven, brand focused healthcare company
Formulation driven, brand focused healthcare company About Influx Healthtech Limited Revenue Mix – H1 FY26 (%) Veterinary & Homecare, 1% Ayurvedic, 4% ▪ Founded in 2020 by Dr. Munir Chandniwala, Influx Healthtech is a contract development and manufacturing organization (CDMO) specializing in nutrace
Slide 9: Strategic milestones
Strategic milestones Transitioned in a Installed liquid fill Acquired additional private limited capsule technology land in Palghar to company expand into veterinary foods; Kicked-off formulation trials 2003 2021 2023 2025 2020 2021 2024 Entered industry Started Started snacking Became public manufa
Slide 10: Agenda
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. 3. Competitive Competitive moats moats 4. Investment rationale 5. Historical business performance 6. Select financial statement data 7. Annexures
Slide 11: Sustainable competitive moats
Sustainable competitive moats Well-diversified product portfolio Formulation driven innovation Robust and integrated business model Strong clientele across geographies and industries Capacity expansion for sustained growth Industry leading certification & compliance systems Passionate and purpose-dr
Slide 12: Well-diversified product portfolio
Well-diversified product portfolio Home Care Dietary /Nutritional Supplements Veterinary Feeds 0.02% 1% 90% 66.8crs. H1 FY26 revenue 4% Ayurvedic /Herbal 5% Cosmetics Our product lines reflect our dedication to bringing cutting edge, science-backed health solutions to consumers Note: Chart is not to
Slide 13: Actively focused on expanding our product portfolio
Actively focused on expanding our product portfolio 2025 • Pet food for cats 2024 • Nutritional oral gel • Ayurvedic gummies • Oral dissolving powder 2023 • Pet food for dogs • Nutrition toppers for pets 2021 • Popped chips • Nutritional gummies 2022 • Wafer protein bars • Peanut butter bar • Liquid
Slide 14: In-house F&D unit: Key driver in creating innovative, market-ready solutions
In-house F&D unit: Key driver in creating innovative, market-ready solutions ▪ Provide development services including formulation development, process development and analytical development ▪ In-house formulation & development (F&D) team focused on creating new formulations based on current health t
Slide 15: Supporting clients across all stages of development and manufacturing
Supporting clients across all stages of development and manufacturing Contact Influx Sample preparation Label designing Finished Healthtech product New product idea Pricing Finalizing packaging Commercial scale production 14
Slide 16: Strong clientele across geographies and industries
Strong clientele across geographies and industries Number of clients Marquee clients 636 559 538 FY23 FY24 FY25 Develop reliable, palatable formulations that ensure consumer acceptance and long-term client success Work closely with clients to refine formulations for feasibility, cost efficiency, and
Slide 17: Capacity expansion for sustained growth
Capacity expansion for sustained growth Nutraceuticals Cosmetics & ayurvedic Pet supplements & homecare Capacity utilization: 65% Capacity utilization: 60% Capacity utilization: 75% 300 5,000 1,000 15,000 1,800 3,000 1,500 10,000 2,000 FY25 Addition H1 FY26 FY25 Addition H1 FY26 FY23 Addition in FY2
Slide 18: Massive increase in output post commissioning of our new capacity
Massive increase in output post commissioning of our new capacity Unit – 1 Nutraceuticals Capacities commercialized in H1 FY26, Unit – 2 Cosmetics & ayurvedic through internal accruals Multi-line production ▪ 480 kg/day: Tablet production ▪ 24,000 bottles/shift: Liquid production ▪ 32,000 sachets/sh
Slide 19: Capex deployment progressing as planned
Capex deployment progressing as planned Unit – 1 Nutraceuticals Unit – 2 CosmeticsMachinery & ayurvedicordered | Funded via IPO proceeds Automated beverage manufacturing line ▪ Capacity: 10,000 bottles/hour ▪ Supports both carbonated and non-carbonated beverage formats Sachet card machine (Single-do
Slide 20: Industry leading certification and compliance systems
Industry leading certification and compliance systems Industry leading certifications and accreditations enhancing our ability to further revenue growth Adherence to high quality standards Prevents unsafe food from reaching consumers Reduces risks like contamination, errors, or unsafe products Build
Slide 21: Awards and recognition
Awards and recognition 2015 2016 2016 2018 2025 Best Nutraceutical Company of Best Sports Supplement Best Sports Supplement Innovative Nutraceuticals Grade A+ Exemplar the Year 2015 in 3rd Party Manufacturing Company of the Manufacturing Company of the of the Year, 2018. Certification, 2025. Certifi
Slide 22: Passionate and purpose-driven team
Passionate and purpose-driven team Dr. M.A. Chandniwala Mrs. Shirin Chandniwala Dr. A.A. Chandniwala Dr. Vipul Patel Mr. Ashok Kumar Jain (MD & Chairman) Whole-time Director Director Independent Director Independent Director Industry experience: 22+ years Industry experience: 12+ years Industry expe
Slide 23: Agenda
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. Competitive moats 4. 4.Investment Investmentrationale rationale 5. Historical business performance 6. Select financial statement data 7. Annexures
Slide 24: Investment rationale: Influx Healthtech Limited
Investment rationale: Influx Healthtech Limited Diversified Product Portfolio Wide-Ranging Client Base Advanced Formulation Development Multi-nutritional tablets, dietary A strong presence across cosmetics, supplements, ayurvedic products, oral Specializes in formulation pharmaceuticals, and homecar
Slide 25: Agenda
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. Competitive moats 4. Investment rationale 5. 2. Historical 5. About business Influx Historical performance Healthtech business Limited performance 6. Select financial statement data 7. Annexures
Slide 26: Historic business performance (1/3)
Historic business performance (1/3) Revenue Revenue from from operations operations (₹ (₹ crs.) crs.) RevenueEBITDA from operations (₹ crs.) (₹ crs.) Revenue from PAToperations (₹ crs.) (₹ crs.) 100 105 21 13 76 17 11 11 7 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 Revenue from Gross operations Pr
Slide 27: Historic business performance (2/3)
Historic business performance (2/3) Revenue fromROE operations 1 (₹ crs.) Revenue from operations Debtor Days (₹ crs.) RevenueInventory from operations Days (₹ crs.) 61.8% 113 112 48.9% 37.0% 66 58 41 18 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 RevenueAsset from operations Turnover (₹ crs.) Reve
Slide 28: Historic business performance (3/3)
Historic business performance (3/3) Revenue fromconcentration Revenue operations (₹1 crs.) Revenue fromconcentration Supplier operations (₹1 crs.) Revenue fromfrom Cash flow operations (₹ crs.) operations 49% 39% 9 39% 48% 7 7 46% 36% FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 Revenue from operati
Slide 29: Agenda
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. Competitive moats 4. Investment rationale 5. Historical business performance 2. 6.About Select Influx Healthtech financial Limited statement data 7. Annexures
Slide 30: Income statement
Income statement ₹ crores unless otherwise mentioned Particulars H1 FY25 H1 FY26 YoY change (%) Revenue from operations 48.1 66.8 39% Cost of materials consumed including finished goods and WIP 29.7 37.5 26% Employee benefits expense 3.9 5.1 30% Other expenses 5.3 9.5 78% Total operating expenses 57
Slide 31: Balance Sheet
Balance Sheet ₹ crores unless otherwise mentioned Assets FY24 FY25 H1 FY26 PPE and intangible assets 13.7 18.8 24.2 Capital work-in-progress 0.0 0.0 0.6 Non-current assets 1.7 2.5 6.2 Cash and cash equivalents 3.6 1.9 2.9 Current investments 0.0 0.0 33.7 Short term loans and advances 0.7 0.8 1.1 Tra
Slide 32: Cashflow statement
Cashflow statement ₹ crores unless otherwise mentioned Cashflow from operating activities FY24 FY25 H1 FY26 Net Profit before tax & extraordinary items 14.9 17.9 13.1 Depreciation & amortization expenses 1.9 2.8 1.7 Other adjustment 0.4 0.0 0.4 Trade receivables -2.3 -16.6 -2.1 Trade payables 0.5 15
Slide 33: Annexures: Industry Outlook
Agenda 1. Executive summary 2. About Influx Healthtech Limited 3. Competitive moats 4. Investment rationale 5. Historical business performance 6. Select financial statement data 7. 7. Annexures Annexures: Industry Outlook
Slide 34: India’s CDMO industry to grow 2x global industry
India’s CDMO industry to grow 2x global industry Global CDMO industry (In $ bn) Levers driving growth of India’s CDMO industry 278 7.2% CAGR Strategic shift toward outsourcing ▪ Pharma firms outsource to CDMOs for cost savings and expertise, with CDMOs offering end-to-end drug development services C
Slide 35: India’s nutraceutical industry: $76 bn opportunity
India’s nutraceutical industry: $76 bn opportunity Global nutraceutical industry (In $ bn) Growth drivers of India’s nutraceutical industry 919 7.6% CAGR Lifestyle shifts with rising health consciousness ▪ Rising health awareness and lifestyle changes are driving demand for nutraceuticals 591 Suppor
Slide 36: Thank you
Thank you For any further information/factory visit request, please contact: Company Investor relations consultant Influx Healthtech Ltd. Capital Bridge Advisory Service Private Ltd Mr. Ashish Shah, CFO Mr. Rutul Shah Mr. Raj Shah, CFA Mr. Hrishit Jhaveri, CFA cs@influxhealthtech.com rutul@capbridge